人免疫球蛋白联合头孢哌酮舒巴坦治疗新生儿肺炎的疗效

Efficacy of human immunoglobulin combined with cefoperazone-sulbactam in the treatment of neonatal pneumonia

目的:探讨人免疫球蛋白联合头孢哌酮舒巴坦治疗新生儿肺炎的疗效。方法:根据治疗方案不同将100例新生儿肺炎患儿分为对照组与研究组,每组各50例。对照组予以头孢哌酮舒巴坦药物治疗;研究组予以头孢哌酮舒巴坦药物+人免疫球蛋白药物治疗。比较两组患儿的临床疗效、血常规、炎症水平、免疫球蛋白水平、临床症状、体征、不良反应、血象恢复情况。结果:实验组患儿的临床疗效较对照组高(P<0.05)。治疗后,两组患儿的外周血白细胞(WBC)、中性粒细胞比值(NEUT)水平均降低(P<0.05),且实验组低于对照组(P<0.05)。治疗后,两组患儿的IgG、IgM及IgA水平均上升(P<0.05),且实验组高于对照组(P<0.05)。治疗后,两组患儿的血清降钙素原(PCT)、白细胞介素6(IL-6)、高敏C反应蛋白(hs-CRP)水平均降低(P<0.05),且实验组低于对照组(P<0.05)。实验组患儿口吐泡沫消失时间、肺部啰音消失时间、体温稳定时间、发绀消失时间、气急消失时间及血象恢复正常时间均短于对照组(P<0.05)。实验组不良并发症总发生率为8.00%,低于对照组的24.00%(P<0.05)。结论:人免疫球蛋白联合头孢哌酮舒巴坦治疗新生儿肺炎患儿的疗效更佳,可改善患儿临床症状、免疫球蛋白与血象变化,减轻炎症因子水平,安全性较高。

Objective:To investigate the effect of human immunoglobulin combined with cefoperazone-sulbactam in the treatment of neonatal pneumonia.Methods:100 cases of neonatal pneumonia were divided into two groups according to the treatment plan,50 cases in each group.The control group was treated with cefoperazone sulbactam,and the study group was treated with cefoperazone sulbactam and human immunoglobulin.The clinical efficacy,blood routine,inflammation level,immunoglobulin level,clinical symptoms,signs,adverse reactions,and blood picture recovery were compared between the two groups.Results:The clinical efficacy of the experimental group was higher than that of the control group(P<0.05).After treatment,the peripheral blood white blood cell(WBC)and neutrophil ratio(NEUT)of the two groups were lower than those before treatment(P<0.05),and the experimental group was lower than the control group(P<0.05).After treatment,the levels of IgG,IgM and IgA in the two groups were higher than those before treatment(P<0.05),and those in the experimental group were higher than those in the control group(P<0.05).After treatment,the serum levels of procalcitonin(PCT),interleukin-6(IL-6)and high-sensitivity C-reactive protein(hs-CRP)in the two groups were lower than those before treatment(P<0.05),and those in the experimental group were lower than those in the control group(P<0.05).Compared with the control group,the experimental group had shorter disappearance time of mouth foam,lung rales,body temperature,cyanosis,shortness of breath and blood picture recovery time(P<0.05).The total incidence of adverse complications in the experimental group was 8.00%,which was lower than 24.00%in the control group(P<0.05).Conclusion:Human immunoglobulin combined with cefoperazone sulbactam is more effective in the treatment of neonatal pneumonia,which can improve the clinical symptoms,immunoglobulin and blood changes,reduce the levels of inflammatory factors,and has good safety.